Site Map Press Room Careers
Financial
Quarterly Results
Financial Highlights
Annual Reports
Business Drivers
Investors
Contact Person
Frequently Asked Questions

Unaudited Quarterly Results for the First Quarter ended 30th June, 2004

(Rs.in Mio)
 

First Quarter Ended

Year ended

Particulars

 30.06.2004 30.06.2003 31.03.2004
  (Unaudited) (Unaudited) (Audited)
Net Sales/Income from Operations 2849.3 3058.7 13410.7
Other Income 23.6 17.4 220.6
Total Income 2872.9 3076.1 13631.3
Expenditure      
 a. (Increase) / Decrease in Stock in Trade -234.6 -175.5 -363.5
 b. Consumption of Raw Materials 1710.9 2070.0 7870.7
 c. Staff Cost 159.5 111.5 513.5
 d. Other Expenditure 816.7 619.9 3221.3
Total expenditure 2452.5 2625.9 11242.0
Profit Before Depreciation, Interest & Tax 420.4 450.2 2389.3
Interest 73.6 60.0 322.5
Depreciation 109.8 70.7 341.6
Profit before taxation 237.0 319.5 1725.2
Provision for Taxation      
a. Current Tax 17.8 69.9 292.7
b. Deferred Tax 38.7 19.1 161.5
c. Tax adjustments of previous years .3 0 .8
Net Profit 180.2 230.5 1270.2
Paid-up Equity Share Capital  253.9 232.5 253.9
(Face value Rs. 5 per share)      
Reserves excluding Revaluation Reserves - - 7309.9
Earnings per share - Not annualised      
Basic (Rs.) 3.55 4.96 26.54
Diluted (Rs.) 3.55 4.94 26.41
Aggregate of Non-promoters Shareholding      
a. Number of Shares 22938206 17956946 22942230
b. Percentage of Shareholding 45.18 38.62 45.19
Notes:
1. The above unaudited results which are subjected to limited review by the Auditors of the Company, were reviewed by the Audit Committee and have been taken on record by the Board at its meeting held on 31.07.2004.
2. The Company has incurred an exchange rate fluctuation loss of Rs.82.3 Millions in Q1 of FY 04-05 as against a gain of Rs.39.0 Millions in Q1 of FY 03-04. The same is regrouped under other expenditure.
3. Exports (F.O.B value) constitute Rs.1294.5 Millions(Rs.1449.6 Millions) of the sales for the quarter.
4. The Company has received USFDA approval for its Unit I(APIs facility) and Unit III (formulation facility).
5. The Company's operations fall within a single primary business segment viz 'Pharmaceutical Products'.
6. Investor complaints pending at the beginning of the quarter: Nil, received: 71, resolved: 71 and lying unresolved at the end of the quarter: Nil.
7. Figures for the previous quarter have been rearranged wherever necessary.
For and on behalf of the Board
Sd/-
Place: Hyderabad K.Nityananda Reddy
Date : 31.07.2004 Managing Director
Site Map Press Room Careers